310 related articles for article (PubMed ID: 24510453)
1. From empiric to mechanism-based therapy for peripheral T cell lymphoma.
Intlekofer AM; Younes A
Int J Hematol; 2014 Mar; 99(3):249-62. PubMed ID: 24510453
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
Rogers AM; Brammer JE
Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
[TBL] [Abstract][Full Text] [Related]
3. Peripheral T-Cell Lymphoma: Moving Toward Targeted Therapies.
Ng SY; Jacobsen ED
Hematol Oncol Clin North Am; 2019 Aug; 33(4):657-668. PubMed ID: 31229161
[TBL] [Abstract][Full Text] [Related]
4. Biomarker-driven management strategies for peripheral T cell lymphoma.
Mulvey E; Ruan J
J Hematol Oncol; 2020 May; 13(1):59. PubMed ID: 32448357
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
Zhang P; Zhang M
Clin Epigenetics; 2020 Nov; 12(1):169. PubMed ID: 33160401
[TBL] [Abstract][Full Text] [Related]
6. Peripheral T cell lymphoma in Asia.
Park S; Ko YH
Int J Hematol; 2014 Mar; 99(3):227-39. PubMed ID: 24481942
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
[TBL] [Abstract][Full Text] [Related]
9. Therapy of Peripheral T Cell Lymphoma: Focus on Nodal Subtypes.
Allen PB; Pro B
Curr Oncol Rep; 2020 Apr; 22(5):44. PubMed ID: 32297075
[TBL] [Abstract][Full Text] [Related]
10. Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
Kanavaros P; Boulland ML; Petit B; Arnulf B; Gaulard P
Leuk Lymphoma; 2000 Jul; 38(3-4):317-26. PubMed ID: 10830738
[TBL] [Abstract][Full Text] [Related]
11. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
Zain JM
Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
[TBL] [Abstract][Full Text] [Related]
12. [Molecular pathogenesis of peripheral T-cell lymphoma (1): angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified and anaplastic large cell lymphoma].
Couronné L; Bastard C; Gaulard P; Hermine O; Bernard O
Med Sci (Paris); 2015 Oct; 31(10):841-52. PubMed ID: 26481023
[TBL] [Abstract][Full Text] [Related]
13. New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.
Ma H; O'Connor OA; Marchi E
Expert Rev Hematol; 2019 Mar; 12(3):137-146. PubMed ID: 30782038
[TBL] [Abstract][Full Text] [Related]
14. T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment.
Casulo C; O'Connor O; Shustov A; Fanale M; Friedberg JW; Leonard JP; Kahl BS; Little RF; Pinter-Brown L; Advani R; Horwitz S
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 28040682
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin in the treatment of CD30+ PTCL.
Barta SK; Gong JZ; Porcu P
Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
[TBL] [Abstract][Full Text] [Related]
16. Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management.
Ong SY; Zain JM
Am J Hematol; 2024 Mar; 99(3):439-456. PubMed ID: 38304959
[TBL] [Abstract][Full Text] [Related]
17. [Present and future perspective of the treatment of peripheral T-cell lymphoma].
Nagai H
Rinsho Ketsueki; 2020; 61(9):1259-1265. PubMed ID: 33162524
[TBL] [Abstract][Full Text] [Related]
18. Development of new agents for peripheral T-cell lymphoma.
Ito Y; Makita S; Tobinai K
Expert Opin Biol Ther; 2019 Mar; 19(3):197-209. PubMed ID: 30658046
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic Aberrations and Targets in Peripheral T-Cell Lymphoma.
Atallah-Yunes SA; Robertson MJ; Davé UP
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):659-665. PubMed ID: 35577752
[TBL] [Abstract][Full Text] [Related]
20. Novel targeted therapies in peripheral T cell lymphoma.
Jagadeesh D; Smith MR
Discov Med; 2013 Jun; 15(85):367-78. PubMed ID: 23819951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
